Sparks commentary - Basilea Pharmaceutica

Healthcare

Sparks - Basilea Pharmaceutica

More on this equity
Basilea’s (SIX: BSLN) milestone march continues
Published by Jyoti Prakash

Basilea has reported another US$1.25m milestone payment for partner Pfizer, triggered by Cresemba sales in the region crossing a pre-defined threshold. This is the fourth milestone payment for Cresemba from the region this year and adds to the already strong H2 performance (c CHF33m/c US$38.5m milestone payments recorded in H224 so far; CHF35m in 2024 to date). The Asia-Pacific region, and in particular China (which accounts for c 20% of the market potential for Cresemba), is of key importance to Basilea, as the company approaches maturity in the US and European markets (market exclusivity until late 2027). Note that Cresemba has recorded in market sales of US$505m for the 12-months ended June 2024, a 20% y-o-y growth.

 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free